FDA Enforcement · May 6, 2026
Drug recall: Ketamine Hydrochloride Injectable Solution, 50mg/ml, (50 mg per mL) Volume: 1 mL, 5265 Kitty Drive,…
cGMP deviations. — Wells Pharma of Houston LLC · Class II · Ongoing
Latest medical news · page 66
The latest headlines across every section, pulled from official and open-access sources.
FDA Enforcement · May 6, 2026
Drug recall: iVIZIA, Sterile Lubricant Eye Drops (Povidone 0.5%), 0.33 Fl oz (10 mL), Made in France, Distributed by:…
Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer. — Thea Pharma, Inc. · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL), well pharma…
cGMP deviations. — Wells Pharma of Houston LLC · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride, Narcotic, (2500 mcg/ 250 mL) (10 mcg per…
cGMP deviations. — Wells Pharma of Houston LLC · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: GenTeal Tears, Lubricant Eye Gel, Sterile, 10g (0.34 Fl oz), Distributed by: Alcon Laboratories, Inc.,…
Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality. — Alcon Research LLC · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: Alendronate Sodium Oral Solution, 70 mg/75 mL, 75 mL, Rx only, 4 x 75 mL Single Dose Bottles, Distr. by:…
This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. — Hikma Pharmaceuticals USA INC · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: fentaNYL Citrate Injectable Solution, NARCOTIC, Cii, 1000 mcg/100 mL (10 mcg per mL), 100 mL bag, Wells…
cGMP deviations. — Wells Pharma of Houston LLC · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope…
Lack of Assurance of Sterility — SCOPE HEALTH · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: fentaNYL Citrate Injectable Solution, Narcotic, CII, 1250 mcg/25mL (50 mcg per mL), 25 mL, wells pharma of…
cGMP deviations. — Wells Pharma of Houston LLC · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: Lidocaine Wound Gel (Benzalkonium Chloride, 0.13% and Lidocaine Hydrochloride, 2%), NET WT 0.5 OZ (14 g),…
Failed PH Specifications — Water-Jel Technologies, LLC · Class III · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: Systane, Lubricant Eye Gel, Night Gel, Sterile, 10g (0.35 oz), Processed in France for: Alcon…
Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality. — Alcon Research LLC · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: Phenylephrine Hydrochloride Injectable Solution, 40mg, 250*mL Bag, wells pharma of Houston, NDC 73702-122-03
cGMP deviations. — Wells Pharma of Houston LLC · Class II · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: Levocarnitine Injection, USP, 1 g/5 mL (200 mg/mL), 5 mL Single-Dose Vial, For intravenous use, Rx Only,…
Labeling: Missing Label — American Regent, Inc. · Class III · Ongoing
FDA Enforcement · May 6, 2026
Drug recall: fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma,…
cGMP deviations. — Wells Pharma of Houston LLC · Class II · Ongoing
FDA Newsroom · May 5, 2026
FDA Expands Market Access, Authorizes New ENDS Products
FDA today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product application (PMTA) pathway.
PLOS Medicine · May 5, 2026
Multimorbidity, health service use, and health insurance by socioeconomic groups in 31 countries: A multi-cohort study
by Yanshang Wang, Chang Cai, Zhenyu Shi, Qian Gao, Alex Bottle, Mansour Taghavi Azar Sharabiani, Joshua Stott, Benedict Hayhoe, Ping He Background The prevalence of physical, psychological, and cognitive multimorbidity is characterised by marked socioeconomic status (SES) inequalities. However, the relationships between multimorbidity patterns—particularly those involving cognitive conditions—and healthcare utilisation, as well as the role of health insurance, remain poorly understood. This study aims to explore healthcare-seeking behaviour among individuals with multimorbidity and assess…
Annals On Call (ACP) · May 4, 2026
Clinical Mastery in Primary Care
Dr. Centor discusses advancing clinical mastery as a strategy to revitalize primary care practice with Dr. Richard Kravitz.
JAMA Clinical Reviews · May 4, 2026
Hepatitis B: Global Insights on Transmission and Treatment
Hepatitis B virus (HBV) infection affects around 254 million people worldwide and causes more than 1 million deaths annually. Author Anna Lok, MD, from the University of Michigan discusses HBV transmission, screening, and treatment with JAMA Associate Editor Beverly Forsyth, MD. Related Content: Hepatitis B Hepatitis B Virus Treatment Gaps in the US Tenofovir and Hepatitis B Virus Transmission During Pregnancy US Newborn Hepatitis B Virus Vaccination Rates
NCI Cancer Currents · May 4, 2026
Your NCI: Top Priorities from AACR 2026
NCI Director Dr. Anthony Letai shares his reflections on this year’s AACR Annual Meeting, including science that stood out and NCI’s leading priorities.
NCI Cancer Currents · May 4, 2026
Your NCI: Top Priorities from AACR 2026
NCI Director Dr. Anthony Letai shares his reflections on this year’s AACR Annual Meeting, including science that stood out and NCI’s leading priorities.
WHO · May 4, 2026
Joint call by the President of the ICRC, the Director-General of WHO and the International President of MSF
Ten years ago, the UN Security Council unanimously adopted Resolution 2286 on health care in armed conflicts. The situation is even worse compared to 10 years ago. Today, we mark not an achievement – we mark a failure. As violence affecting medical facilities, transport and personnel continues unabated, the harm this resolution sought to prevent has not diminished. It has continued and, in many contexts, intensified. As the heads of the International Committee of the Red Cross (ICRC), the World Health Organization (WHO), and Médecins Sans Frontières (MSF), we join others in the international…
NHS England · May 3, 2026
‘1-minute’ immunotherapy jab rolled out on NHS for tens of thousands with cancer
Tens of thousands of patients could benefit from a ‘rapid’ new immunotherapy jab on the NHS for over a dozen different cancers, which can be given in just 60 seconds. The NHS is rolling out a new injectable form of pembrolizumab (Keytruda) which can slash the time the treatment takes by up to 90%, to […]
WHO · May 1, 2026
WHO Member States agree to extend negotiations on Pathogen Access and Benefit Sharing annex
Member States of the World Health Organization (WHO) have progressed work on the Pathogen Access and Benefit Sharing (PABS) annex, a key part of the WHO Pandemic Agreement, and today agreed additional time was needed to finalize the framework for ensuring a better, more equitable, response to future pandemics. Countries today ended the resumed session of the sixth meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement in Geneva, focused on the PABS system. The outcome of this work will be presented to the Seventy-ninth World Health Assembly (WHA) later this month…
FDA Newsroom · May 1, 2026
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.